COMPANY PROFILE // THE 014 REPORT
Emmaus Life Sciences, Inc.
EMMA (OTC) · Formerly: MYnd Analytics, Inc.; CNS RESPONSE, INC.; STRATIVATION, INC.; SalesTactix, Inc.; AGE RESEARCH INC
Assembled from 1 government source in 3.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- AmberNT 10-Q filed on 2026-11-16: notice that a periodic report would be late (2 such notices in 24 months).
- Amber3 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-04-17: a pattern of leadership change.
- Amber8-K Item 4.01 filed: change in the company's certifying accountant (auditor) on 2025-05-06 (last 24 months).
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Emmaus Life Sciences, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Torrance, CA; listed as EMMA (OTC).[source] It reported revenue of $12.5 million for the fiscal year ended 2025-12-31.[source] It has filed 17 documents with the SEC in the last 12 months; the latest is Form 8-K, filed 2026-11-19.[source] Seraphix flags 3 items from these records: 8-K Item 4.01 filed; 3 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-04-17; NT 10-Q filed on 2026-11-16.[source]
- red0
- amber3
- info0
- CLEAR26
- POSSIBLE MATCH0
- MATCH0
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0000822370 | source |
| EIN | 87-0419387 | source |
| Business address (SEC) | 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE, CA, 90503 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
ADDRESS · ZIP CODE
Location context
At the same address (7)
- AUTISM SOCIETY OF AMERICA LOS ANGELES INC · IRS-registered organization
- LEBOB FOUNDATION · IRS-registered organization
- SHURL AND KAY CURCI FOUNDATION · IRS-registered organization
- SOUTHERN CALIFORNIA SCHOOL OF MEDIC INE · IRS-registered organization
- FAHMYLY FOUNDATION · IRS-registered organization
- PLL ASSISTS INC · IRS-registered organization
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-19 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-11-19 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-16 filing NT 10-Q · SEC EDGAR
- 2026-08-14 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-08-14 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-15 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-05-15 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-04-17 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-04-14 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-03-31 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-03-31 filing Annual report (10-K) · SEC EDGAR
- 2026-03-04 filing 8-K items 1.01,9.01 · SEC EDGAR
- 2025-12-31 filing 8-K items 1.01,8.01,9.01 · SEC EDGAR
- 2025-12-22 filing 8-K items 1.01,2.03,3.02,9.01 · SEC EDGAR
- 2025-12-19 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2025-11-14 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2025-11-14 filing Quarterly report (10-Q) · SEC EDGAR
- 2025-08-14 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2025-08-14 filing Quarterly report (10-Q) · SEC EDGAR
- 2025-07-01 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2025-05-15 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2025-05-15 filing Quarterly report (10-Q) · SEC EDGAR
- 2025-05-06 filing 8-K items 4.01,9.01 · SEC EDGAR
- 2025-04-14 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2025-04-14 filing Annual report (10-K) · SEC EDGAR
- 2025-04-01 filing NT 10-K · SEC EDGAR
- 2024-11-19 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2024-11-19 filing Quarterly report (10-Q) · SEC EDGAR
- 2024-11-14 filing NT 10-Q · SEC EDGAR
- 2024-11-06 officer change 8-K items 5.02,9.01 · SEC EDGAR
158 earlier entries
- 2024-10-25 filing 8-K items 4.01,9.01
- 2024-10-04 officer change 8-K items 5.02,9.01
- 2024-09-10 filing 8-K items 2.02,4.01,9.01
- 2024-09-10 filing Quarterly report (10-Q)
- 2024-09-10 filing Quarterly report (10-Q)
- 2024-08-15 filing NT 10-Q
- 2024-07-17 officer change 8-K items 5.02,9.01
- 2024-07-03 filing 8-K items 2.02,9.01
- 2024-07-03 filing Annual report (10-K)
- 2024-05-28 filing 8-K items 5.03,9.01
- 2024-04-01 filing NT 10-K
- 2024-02-26 filing 8-K items 1.01,2.03,3.02,9.01
- 2023-12-20 filing 3/A
- 2023-12-20 filing 8-K items 1.01,3.02,9.01
- 2023-11-14 filing 8-K items 2.02,9.01
- 2023-11-14 filing Quarterly report (10-Q)
- 2023-10-04 officer change 8-K items 5.02,9.01
- 2023-08-23 officer change 8-K items 5.02,9.01
- 2023-08-14 filing 8-K items 2.02,9.01
- 2023-08-14 filing Quarterly report (10-Q)
- 2023-05-15 filing 8-K items 2.02,9.01
- 2023-05-15 filing Quarterly report (10-Q)
- 2023-03-31 filing 8-K items 2.02,9.01
- 2023-03-31 filing Annual report (10-K)
- 2023-03-07 filing 8-K items 3.02,9.01
- 2023-02-21 filing SC 13D/A
- 2023-01-31 filing D
- 2023-01-20 filing D
- 2023-01-19 officer change 8-K items 3.02,5.02,9.01
- 2022-12-12 filing 8-K items 5.07,9.01
- 2022-11-15 filing 8-K items 2.02,9.01
- 2022-11-14 filing Quarterly report (10-Q)
- 2022-11-09 filing SC 13D/A
- 2022-10-31 filing Proxy statement
- 2022-10-21 filing PRE 14A
- 2022-10-06 officer change 8-K items 5.02
- 2022-09-30 officer change 8-K items 5.02
- 2022-08-19 filing 8-K items 1.01,2.03,9.01
- 2022-08-15 filing 8-K items 2.02,9.01
- 2022-08-15 filing Quarterly report (10-Q)
- 2022-08-10 officer change 8-K items 5.02,9.01
- 2022-07-01 filing 10-K/A
- 2022-06-30 filing D
- 2022-06-10 officer change 8-K items 5.02,9.01
- 2022-05-13 filing 8-K items 2.02,9.01
- 2022-05-13 filing Quarterly report (10-Q)
- 2022-03-31 filing 8-K items 2.02,9.01
- 2022-03-31 filing Annual report (10-K)
- 2022-02-17 filing SC 13D/A
- 2022-01-10 officer change 8-K items 5.02
- 2021-12-30 filing S-8
- 2021-12-01 filing SC 13D/A
- 2021-11-29 officer change 8-K items 5.02,5.07,9.01
- 2021-11-12 filing Quarterly report (10-Q)
- 2021-10-12 filing Proxy statement
- 2021-10-12 filing 8-K items 1.01,9.01
- 2021-09-30 filing PRE 14A
- 2021-09-01 filing Quarterly report (10-Q)
- 2021-09-01 filing Quarterly report (10-Q)
- 2021-08-26 filing Quarterly report (10-Q)
- 2021-08-26 filing Quarterly report (10-Q)
- 2021-08-26 filing Quarterly report (10-Q)
- 2021-08-10 filing 10-K/A
- 2021-08-10 filing 8-K items 4.02,9.01
- 2021-07-22 filing SC 13D/A
- 2021-05-19 filing 8-K items 8.01,9.01
- 2021-05-17 filing NT 10-Q
- 2021-05-04 filing Annual report (10-K)
- 2021-03-31 filing NT 10-K
- 2021-02-22 filing 8-K items 1.01,2.03,9.01
- 2021-02-16 filing D
- 2021-02-16 filing 8-K items 1.01,2.03,3.02,9.01
- 2021-01-25 filing Annual report (10-K)
- 2020-11-13 filing 8-K items 1.01,2.03,9.01
- 2020-11-05 filing 8-K items 4.01,9.01
- 2020-10-29 filing 8-K items 7.01,9.01
- 2020-10-20 filing 8-K items 1.01
- 2020-10-09 filing D/A
- 2020-10-08 filing 8-K/A items 3.02
- 2020-10-07 filing D/A
- 2020-10-07 filing D
- 2020-09-25 filing 8-K/A items 9.01
- 2020-09-24 filing 8-K items 1.01,2.03,9.01
- 2020-09-17 filing 8-K items 4.01
- 2020-09-01 officer change 8-K items 5.02
- 2020-08-07 filing D
- 2020-07-31 filing 8-K items 8.01,9.01
- 2020-07-08 filing 8-K items 4.02,9.01
- 2020-05-18 filing NT 10-Q
- 2020-05-15 filing NT 10-K
- 2020-04-30 filing 8-K/A items 8.01
- 2020-04-02 filing SC 13D/A
- 2020-03-31 officer change 8-K items 5.02
- 2020-03-27 filing 8-K items 8.01
- 2020-03-03 filing 424B5
- 2020-03-03 filing 8-K items 1.01,8.01,9.01
- 2020-02-27 filing 8-K items 1.01,2.03,9.01
- 2020-01-06 filing 8-K items 4.01,9.01
- 2019-12-23 filing 8-K items 1.01
- 2019-12-02 filing 3/A
- 2019-11-13 filing Quarterly report (10-Q)
- 2019-11-12 filing 8-K items 8.01,9.01
- 2019-11-08 filing 25-NSE
- 2019-10-29 filing 8-K items 8.01,9.01
- 2019-10-25 filing 424B5
- 2019-10-24 filing 8-K items 4.01,9.01
- 2019-10-11 filing 8-K items 8.01,9.01
- 2019-10-08 filing 3/A
- 2019-10-01 officer change 8-K items 5.02
- 2019-09-30 filing 8-K items 5.03
- 2019-09-12 filing S-8
- 2019-09-10 filing 8-K items 3.01,8.01,9.01
- 2019-09-09 filing 3/A
- 2019-08-14 filing 8-K/A items 9.01
- 2019-08-14 filing Quarterly report (10-Q)
- 2019-08-05 filing 3/A
- 2019-08-02 filing SC 13D
- 2019-07-26 filing 3/A
- 2019-07-26 filing 3/A
- 2019-07-25 filing 3/A
- 2019-07-22 officer change 8-K items 2.01,3.01,3.03,5.01,5.02,5.03,8.01,9.01
- 2019-07-12 filing 8-K items 5.07
- 2019-07-12 name change Name changed from MYnd Analytics, Inc.
- 2019-07-09 filing 8-K items 8.01,9.01
- 2019-07-09 filing 425
- 2019-06-28 officer change 8-K items 1.01,3.03,5.02,9.01
- 2019-06-20 filing 8-K items 7.01,9.01
- 2019-06-14 filing 424B3
- 2019-06-11 filing EFFECT
- 2019-06-11 filing CORRESP
- 2019-06-11 filing S-4/A
- 2019-06-10 filing S-4/A
- 2019-06-10 filing 8-K items 1.01,9.01
- 2019-05-30 filing UPLOAD
- 2019-05-24 filing 424B5
- 2019-05-23 filing 425
- 2019-05-23 filing 8-K items 1.01,7.01,9.01
- 2019-05-13 filing 8-K items 7.01,8.01,9.01
- 2019-05-13 filing 425
- 2019-05-13 filing Quarterly report (10-Q)
- 2019-05-09 filing CORRESP
- 2019-05-02 filing UPLOAD
- 2019-04-17 filing 8-K items 8.01,9.01
- 2019-04-17 filing 425
- 2019-04-04 filing 8-K items 7.01,8.01,9.01
- 2019-04-04 filing 425
- 2019-03-05 filing 8-K items 7.01,8.01,9.01
- 2019-03-05 filing 425
- 2019-02-25 filing UPLOAD
- 2019-02-22 filing 8-K items 3.01,8.01
- 2019-02-22 filing 425
- 2019-02-14 filing 8-K items 8.01,9.01
- 2019-02-14 filing 425
- 2019-02-14 filing Quarterly report (10-Q)
- 2015-12-10 name change Name changed from CNS RESPONSE, INC.
- 2007-03-01 name change Name changed from STRATIVATION, INC.
- 2005-08-23 name change Name changed from SalesTactix, Inc.
- 2004-08-05 name change Name changed from AGE RESEARCH INC
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-19 (within 7 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-11-19 (within 7 days) 10-Q filed
- 2026-11-16 (within 7 days) NT 10-Q filed (NOTIFICATION OF LATE FILING)
- 2026-08-14 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-08-14 (older) 10-Q filed
- 2026-05-15 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-05-15 (older) 10-Q filed
- 2026-04-17 (older) 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- No listing symbol is held for this company.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
1 possible match held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 822370 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | EMMA / OTC | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 870419387 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0000822370 | SEC EDGAR / IRS |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $12,453,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-20 10:23 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$7,492,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 10:23 UTC | Report an error |
| Total assets (at 2025-12-31) | $21,436,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 10:23 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | -$63,608,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 10:23 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $2,127,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-20 10:23 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| State of incorporation | DE | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| Business address | 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE, CA, 90503 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| Exchanges | OTC | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$11,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 10:23 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $1,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-20 10:23 UTC | Report an error |
| Long-term debt (at 2025-12-31) | $27,128,000 | 2025-12-31 | 10-K, XBRL LongTermDebt | as filed | 2026-11-20 10:23 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $1,800,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-20 10:23 UTC | Report an error |
| Form D total offering amount (D filed 2023-01-31) | $235,000 | 2023-01-31 | D | as filed | 2026-11-20 10:23 UTC | Report an error |
| Form D total amount sold (D filed 2023-01-31) | $0 | 2023-01-31 | D | as filed | 2026-11-20 10:23 UTC | Report an error |
| Form D industry group | Pharmaceuticals | 2023-01-31 | D | as filed | 2026-11-20 10:23 UTC | Report an error |
| Form D revenue range | $5,000,001 - $25,000,000 | 2023-01-31 | D | as filed | 2026-11-20 10:23 UTC | Report an error |
| Form D date of first sale | 2023-01-30 | 2023-01-31 | D | as filed | 2026-11-20 10:23 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-19 · accession 0001193125-26-467388
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $1,892,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-19 | 0001193125-26-467388 | 2026-11-20 10:23 UTC | Report an error |
| Net income (loss) | -$4,741,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-19 | 0001193125-26-467388 | 2026-11-20 10:23 UTC | Report an error |
| Interest expense | $1,865,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-19 | 0001193125-26-467388 | 2026-11-20 10:23 UTC | Report an error |
| Cash and cash equivalents | $971,000 | at 2026-09-30 | 10-Q | 2026-11-19 | 0001193125-26-467388 | 2026-11-20 10:23 UTC | Report an error |
| Debt due in the next 12 months | $196,000 | at 2026-09-30 | 10-Q | 2026-11-19 | 0001193125-26-467388 | 2026-11-20 10:23 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-19 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-11-19 Filing 10-Q filed
- 2026-11-16 Filing NT 10-Q filed (NOTIFICATION OF LATE FILING)
- 2026-08-14 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-08-14 Filing 10-Q filed
- 2026-05-15 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-05-15 Filing 10-Q filed
- 2026-04-17 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-04-14 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-03-31 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-03-31 Filing 10-K filed
- 2026-03-04 Filing 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2025-12-31 Filing 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
- 2025-12-22 Filing 8-K filed: Item 1.01 material agreement; Item 2.03 new financial obligation; Item 3.02 unregistered equity sale; Item 9.01 exhibits
- 2025-12-19 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2025-11-14 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-11-14 Filing 10-Q filed
- 2025-08-14 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-08-14 Filing 10-Q filed
- 2025-07-01 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2025-05-15 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-05-15 Filing 10-Q filed
- 2025-05-06 Filing 8-K filed: Item 4.01 auditor change; Item 9.01 exhibits
- 2025-04-14 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-04-14 Filing 10-K filed
8-K item text, as filed (excerpts)
- 2026-11-19 8-K Item 2.02, Results of Operation and Financial Condition
On November 18, 2026, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) issued a press release announcing our results of operations and financial condition as of and for the three and nine months ended September 30, 2026, a copy of which is included as Exhibit 99.1 to this Current Report and incorporated herein by reference. The information included in this Item 2.02 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange… the 8-K · retrieved 2026-11-20 10:23 UTC - 2026-08-14 8-K Item 2.02, Results of Operation and Financial Condition
On August 14, 2026, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) issued a press release announcing our results of operations and financial condition as of and for the three and six months ended June 30, 2026, a copy of which is included as Exhibit 99.1 to this Current Report and incorporated herein by reference. The information included in this Item 2.02 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act… the 8-K · retrieved 2026-11-20 10:23 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
1 state and city record carry this company's exact name, from 1 source. Possible matches only.
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchMYnd Analytics · name equals 'Mynd Analytics' but other unrelated entities share it · sx:ctgov:h50bcf366e99e6173 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/822370.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0000822370. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.